Relapsed Non Hodgkin Lymphoma Clinical Trial
Official title:
Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Phase I/II trial, with the aim of evaluating the efficacy of venetoclax to the backbone of rituximab-lenalidomide in patients with relapsed/refractory MCL.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04923789 -
A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma
|
||
| Active, not recruiting |
NCT04150913 -
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
|
Phase 2 | |
| Active, not recruiting |
NCT03778619 -
MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04637763 -
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
|
Phase 1 | |
| Recruiting |
NCT03938987 -
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ΞΆ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01811368 -
Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
|
Phase 2 | |
| Recruiting |
NCT03774654 -
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
|
Phase 1 | |
| Completed |
NCT03042585 -
Autologous Transplant Using Dose-Escalated Total Body Irradiation & Cyclophosphamide & Palifermin for NHL
|
N/A | |
| Recruiting |
NCT05053659 -
Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma
|
Phase 1 | |
| Completed |
NCT05006534 -
Polatuzumab Vedotin in Patients With Relapsed and Refractory Diffuse Large B Cell Lymphoma
|
||
| Recruiting |
NCT03196830 -
CAR-T for R/R B-NHL
|
Phase 2 | |
| Completed |
NCT04464590 -
Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT
|
||
| Recruiting |
NCT03091933 -
Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)
|
Phase 1/Phase 2 | |
| Terminated |
NCT04978779 -
A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
|
Phase 1 | |
| Recruiting |
NCT05260957 -
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
|
Phase 2 | |
| Not yet recruiting |
NCT03719989 -
Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT04539444 -
A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma
|
Phase 2 | |
| Completed |
NCT03892421 -
Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03540303 -
Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma
|
Phase 1 |